Fennec Pharmaceuticals Inc. (FENC)

NASDAQ: FENC · IEX Real-Time Price · USD

6.03

-0.24 (-3.83%)

At close: Jul 2, 2024, 4:00 PM

6.00

-0.03 (-0.50%)

After-hours: Jul 2, 2024, 5:05 PM EDT

Fennec Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2002
Revenue	21.25	1.54	0	0.17	0	Upgrade
Revenue Growth (YoY)	1284.50%	-	-	-	-	Upgrade
Cost of Revenue	1.26	0.09	0	0	0	Upgrade
Gross Profit	19.99	1.45	0	0.17	0	Upgrade
Selling, General & Admin	32.71	20.51	12.24	12.95	7.4	Upgrade
Research & Development	0.06	3.53	4.98	5.11	5.61	Upgrade
Operating Expenses	32.76	24.04	17.22	18.06	13.01	Upgrade
Operating Income	-12.77	-22.59	-17.22	-17.89	-13.01	Upgrade
Interest Expense / Income	3.39	0.98	0.13	0.01	0	Upgrade
Other Expense / Income	-0.12	0.15	-0	0.22	-0.23	Upgrade
Pretax Income	-16.05	-23.71	-17.35	-18.11	-12.78	Upgrade
Net Income	-16.05	-23.71	-17.35	-18.11	-12.78	Upgrade
Shares Outstanding (Basic)	27	26	26	24	20	Upgrade
Shares Outstanding (Diluted)	27	26	26	24	20	Upgrade
Shares Change	1.14%	1.03%	9.71%	19.14%	5.04%	Upgrade
EPS (Basic)	-0.60	-0.90	-0.67	-0.76	-0.64	Upgrade
EPS (Diluted)	-0.60	-0.90	-0.67	-0.76	-0.64	Upgrade
Free Cash Flow	-17.14	-18.06	-14.22	-15.6	-9.06	Upgrade
Free Cash Flow Per Share	-0.65	-0.69	-0.55	-0.66	-0.46	Upgrade
Gross Margin	94.08%	94.40%	-	100.00%	-	Upgrade
Operating Margin	-60.09%	-1471.60%	-	-10520.59%	-	Upgrade
Profit Margin	-75.50%	-1544.89%	-	-10652.35%	-	Upgrade
Free Cash Flow Margin	-80.67%	-1176.42%	-	-9173.53%	-	Upgrade
EBITDA	-12.65	-22.74	-17.22	-18.1	-12.78	Upgrade
EBITDA Margin	-59.53%	-1481.17%	-	-10647.06%	-	Upgrade
EBIT	-12.65	-22.74	-17.22	-18.1	-12.78	Upgrade
EBIT Margin	-59.53%	-1481.17%	-	-10647.06%	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).